Baidu
map

Obstet Gynecol:护理干预对使用间歇性加压装置的依从性改变

2015-11-04 candy &kelly MedSci原创

目的:研究经剖宫产或良性妇科手术术后的患者,在经护理教育后接受序贯压缩装置的依从性改变情况。方法:我们在大学医学中心进行了一项前瞻性观察性研究,调查所有需要规定佩戴序贯加压装置的剖腹产术后或良性妇科手术术后的患者(会以英语沟通)。研究时间共计4个月,以不同的月份分为4组。第一个月无干预,测量基线观测值;第二个月对患者结构化教育;第三个月进行护理教育;最后一个月同时施加以上两种干预。每日观察两次。所

术后静脉血栓形成造成了实际的发病率和死亡率。血栓形成主要发生在多达15 - 30%的妇科手术中,剖腹产血栓形成的风险是顺产的5倍到10倍。美国胸科医师学会和美国妇产科学院(大学)都有对此疾病的风险分层和预防策略指南。序贯(间歇性)加压装置或加压弹力袜的机械性预防和低分子肝素或未分离肝素的药物性预防被认为可有效预防静脉血栓的形成。

目的:对经剖宫产或良性妇科手术术后的患者,在经护理教育后接受间歇性加压装置的依从性改变情况进行研究。

方法:我们在大学医学中心进行了一项前瞻性观察性研究,调查所有需要规定佩戴序贯加压装置的剖腹产术后或良性妇科手术术后的患者(会以英语沟通)。研究时间共计4个月,以不同的月份分为4组。第一个月无干预,测量基线观测值;第二个月对患者结构化教育;第三个月进行护理教育;最后一个月同时施加以上两种干预。每日观察两次。所有的教育干预和观察测量都由两位研究者共同参与并记录。观察记录病人走动、坐立亦或卧床,与同一时刻序贯加压装置的应用、管道连接和机器供电的状态。

结果:研究共记录228例患者的859次测量值。住院天数从1到13不等(平均 2.40 天,中位天数为 2 天)。依从性组间无差异(P=.44),其中第一个月为230例有141例依从(61.3%);第二个月为194例有106例依从(54.6%);第三个月为277例有155例依从(56.0%);第四个月为158例有95例依从(60.1%)。随着术后天数的增加,记录下的数据显示并未有连续性(OR 1.18每日,95%置信区间为1.07-1.30)。患者依从性差的最常见原因是: “护士说我不再需要它们了”(在共362次观察中共有82次出现如上情况(22.6%))。总体而言,与妇科手术相比,剖宫产术术后的依从性最低(272/519 [52.4%] vs 225/340 [66.2%],P<.001).。

结论:研究发现遵守术后使用序贯加压设备的占58%,依从性没有因为针对患者的护理教育干预而得到改善。

原始出处:


Brady MA, Carroll AW,et al.Sequential compression device compliance in postoperative obstetrics and gynecology patients.Obstet Gynecol. 2015 Jan;125(1):19-25.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1815740, encodeId=ca431815e4027, content=<a href='/topic/show?id=305c9e26832' target=_blank style='color:#2F92EE;'>#间歇性加压装置#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97268, encryptionId=305c9e26832, topicName=间歇性加压装置)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca6a2500099, createdName=more is better!, createdTime=Wed May 25 06:16:00 CST 2016, time=2016-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043873, encodeId=13f320438e371, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Sep 10 11:16:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954998, encodeId=f248195499843, content=<a href='/topic/show?id=732f9e265d7' target=_blank style='color:#2F92EE;'>#间歇性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97265, encryptionId=732f9e265d7, topicName=间歇性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Dec 12 07:16:00 CST 2015, time=2015-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011209, encodeId=c5d6201120953, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Thu Mar 24 01:16:00 CST 2016, time=2016-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319255, encodeId=006b131925536, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Fri Nov 06 12:16:00 CST 2015, time=2015-11-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1815740, encodeId=ca431815e4027, content=<a href='/topic/show?id=305c9e26832' target=_blank style='color:#2F92EE;'>#间歇性加压装置#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97268, encryptionId=305c9e26832, topicName=间歇性加压装置)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca6a2500099, createdName=more is better!, createdTime=Wed May 25 06:16:00 CST 2016, time=2016-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043873, encodeId=13f320438e371, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Sep 10 11:16:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954998, encodeId=f248195499843, content=<a href='/topic/show?id=732f9e265d7' target=_blank style='color:#2F92EE;'>#间歇性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97265, encryptionId=732f9e265d7, topicName=间歇性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Dec 12 07:16:00 CST 2015, time=2015-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011209, encodeId=c5d6201120953, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Thu Mar 24 01:16:00 CST 2016, time=2016-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319255, encodeId=006b131925536, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Fri Nov 06 12:16:00 CST 2015, time=2015-11-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1815740, encodeId=ca431815e4027, content=<a href='/topic/show?id=305c9e26832' target=_blank style='color:#2F92EE;'>#间歇性加压装置#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97268, encryptionId=305c9e26832, topicName=间歇性加压装置)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca6a2500099, createdName=more is better!, createdTime=Wed May 25 06:16:00 CST 2016, time=2016-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043873, encodeId=13f320438e371, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Sep 10 11:16:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954998, encodeId=f248195499843, content=<a href='/topic/show?id=732f9e265d7' target=_blank style='color:#2F92EE;'>#间歇性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97265, encryptionId=732f9e265d7, topicName=间歇性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Dec 12 07:16:00 CST 2015, time=2015-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011209, encodeId=c5d6201120953, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Thu Mar 24 01:16:00 CST 2016, time=2016-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319255, encodeId=006b131925536, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Fri Nov 06 12:16:00 CST 2015, time=2015-11-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1815740, encodeId=ca431815e4027, content=<a href='/topic/show?id=305c9e26832' target=_blank style='color:#2F92EE;'>#间歇性加压装置#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97268, encryptionId=305c9e26832, topicName=间歇性加压装置)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca6a2500099, createdName=more is better!, createdTime=Wed May 25 06:16:00 CST 2016, time=2016-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043873, encodeId=13f320438e371, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Sep 10 11:16:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954998, encodeId=f248195499843, content=<a href='/topic/show?id=732f9e265d7' target=_blank style='color:#2F92EE;'>#间歇性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97265, encryptionId=732f9e265d7, topicName=间歇性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Dec 12 07:16:00 CST 2015, time=2015-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011209, encodeId=c5d6201120953, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Thu Mar 24 01:16:00 CST 2016, time=2016-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319255, encodeId=006b131925536, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Fri Nov 06 12:16:00 CST 2015, time=2015-11-06, status=1, ipAttribution=)]
    2016-03-24 yhy100200
  5. [GetPortalCommentsPageByObjectIdResponse(id=1815740, encodeId=ca431815e4027, content=<a href='/topic/show?id=305c9e26832' target=_blank style='color:#2F92EE;'>#间歇性加压装置#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97268, encryptionId=305c9e26832, topicName=间歇性加压装置)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca6a2500099, createdName=more is better!, createdTime=Wed May 25 06:16:00 CST 2016, time=2016-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043873, encodeId=13f320438e371, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Sep 10 11:16:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954998, encodeId=f248195499843, content=<a href='/topic/show?id=732f9e265d7' target=_blank style='color:#2F92EE;'>#间歇性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97265, encryptionId=732f9e265d7, topicName=间歇性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Dec 12 07:16:00 CST 2015, time=2015-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011209, encodeId=c5d6201120953, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Thu Mar 24 01:16:00 CST 2016, time=2016-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319255, encodeId=006b131925536, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Fri Nov 06 12:16:00 CST 2015, time=2015-11-06, status=1, ipAttribution=)]
    2015-11-06 fyxzlh

相关资讯

JOT:下肢骨折患者静脉血栓栓塞症的预防

背景:先前研究发现,对单一膝下骨折的病人行静脉造影检查,在被检查患者中有10%–40%可以发现其罹患无症状深静脉血栓。然而,因为条件上的限制,无法对每个此类患者常规进行静脉造影检查,所以深静脉血栓症在临床上的发病率仍属未知,其对患者的风险程度亦无法把握。在不同指南中提到的常规血栓预防措施对患者的正面作用及相关的临床实践指导都有所不同。方法:在本次多中心、双盲实验中,265位有手术指证的单一膝下骨折

AJOG:阴道分娩住院期间VTE发生率及风险因素研究

国际上主流的临床指南推荐,在行阴道分娩住院期间时,伴有其他风险因素的女性,应行静脉血栓栓塞症VTE的预防治疗。而美国临床指南推荐VTE高风险人群才应预防治疗,这是很小的一部分孕妇。Friedman AM等人通过美国全民数据库收集了2006年——2012年共2,673,986名阴道分娩住院女性数据,以分析VTE的发生率和预防治疗情况;同时该研究评估了药物预防以及器械预防治疗情况。在评估预防

JAMA:内脏静脉血栓形成的患者抗凝治疗获益可能大于风险

    已知的关于内脏静脉血栓形成(SVT)患者的长期临床结果仅有一少部分信息。为了评估一个大型国际队列研究中的SVT患者的出血,血栓性事件和死亡率,研究人员进行了此项研究。    该项前瞻性队列研究从2008年5月2日开始,2014年1月30日完成,在专门从事血栓栓塞性疾病的管理以医院为基础的中心进行;2014年1月30日2年随访时间完成,数据分析从201

J Thromb Haemost:癌症并发静脉血栓应用阿哌沙班治疗

J Thromb Haemost:癌症并发静脉血栓应用阿哌沙班治疗背景:AMPLIFY试验比较应用阿哌沙班和依诺肝素/华法林治疗急性静脉栓塞(VTE)。目的:亚组分析比较阿哌沙班和依诺肝素/华法林治疗癌症存在VTE的有效性和安全性。方法:症状性VTE患者随机分为阿哌沙班或依诺肝素/华法林治疗。主要效果预后以及安全预后分别为:VTE复发或VTE相关死亡以及严重出血。结果:共有5395名患者,其中16

JAMA:维生素k拮抗剂治疗静脉血栓,长期or短期疗效

临床问题 :长期(超过3个月)和短期维生素k拮抗剂疗法是否在反复性静脉血栓形成、主要出血和症状性静脉血栓栓塞的死亡率的发生率上有所不同? 关键 :长效的VKAs疗法可降低反复性VTE的风险而增加主要出血的风险,相比下,短效VKAs疗法可以降低病人的症状性 VTE风险,但是两者在死亡率方面没有差别。 急性VTE的病人的VKAs最佳使用时间目前还不清楚。VKAs使用时间的决定必须平

Baidu
map
Baidu
map
Baidu
map